FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a compound of formula (I):
or a pharmaceutically acceptable salt thereof, where X, R0, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined in claim 1. Invention also relates to a method of producing said compound of formula (I), use thereof for preparing a medicament for treating cancer, where JAK and/or FLT3 inhibition may be useful, to use thereof for preparing a medicament for treating leukemia, particularly acute myeloid leukemia, as well as to a pharmaceutical composition for use in treating cancer, where inhibition of JAK and/or FLT3 containing said compound can be beneficial.
EFFECT: technical result is creation of new and more powerful double FLT3-JAK inhibitors, providing the best result for patients with high risk of acute myeloid leukemia.
19 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | 2016 |
|
RU2729609C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| PYPERIDINYL NAPHTHYLUXIC ACIDS | 2012 |
|
RU2628083C2 |
| ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE DERIVATIVES OF AROMATICS, PHARMACEUTICAL COMPOSITION BASED ON THEM AND WAY OF TREATMENT AGAINST ABNORMALITIES RESPONSIVE TO DOPAMINE D RECEPTOR LIGAND TREATMENT, WITH THEIR HELP | 2005 |
|
RU2442781C2 |
| NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
| PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS FOR APPLICATION | 2012 |
|
RU2638552C2 |
| NEW SUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF S-NITROZOGLUTATION-REDUCTASE INHIBITORS | 2011 |
|
RU2599144C2 |
| NOVEL PIRIDAZONES AND TRIAZINONES FOR TREATMENT AND PREVENTING OF HEPATITIS B VIRUS INFECTION | 2015 |
|
RU2664329C1 |
| THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | 2014 |
|
RU2703273C2 |
| NEW BENZODIAZEPINE DERIVATIVES | 2019 |
|
RU2799340C2 |
